Lumakras Market Report
23/08/2024 Alternative Treatments
Price: 3776.00 US$
Description
According to the study by Next Move Strategy Consulting, the growth drivers for the Lumakras Market include its pioneering role as the first FDA-approved KRAS G12C inhibitor for treating non-small cell lung cancer (NSCLC), addressing a previously untreatable genetic mutation. The increasing incidence of NSCLC and the rising demand for targeted therapies are key factors propelling its market expansion.
Comments
Next Move Strategy Consulting
Company
More Details